ArticleProbiotics and antimicrobial proteins2026
Strain-Specific Lactobacillus Probiotics Intervention in Mitigating Obesity and Metabolic Dysregulation via Gut Microbiota Modulation in a Mouse Model of High-Fat Diet.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and associated chronic diseases are major challenges to good health globally. Therapies based on probiotic modalities are rapidly gaining attention. The current study highlights the strain-specific effects of probiotics Lacticaseibacillus rhamnosus GG ATCC 53103 (LR), Lactiplantibacillus plantarum ATCC 8014 (LP), and Lactobacillus delbrueckii subsp. lactis ATCC 12315 (LD) on obesity, metabolic health, and gut microbiota in C57BL/6 mice on either a high-fat diet (23.71% fat) or standard diet (5.5% fat). Eight groups were assessed over eight weeks with or without probiotic supplementation. LR in the HFD cohort (LR-H) demonstrated the greatest efficacy, reducing weight gain by 25.1% (6.26 ± 0.61 g vs. 8.36 ± 1.02 g), visceral adipose tissue (VAT) by 11.1% (2.16 ± 0.10 g vs. 2.43 ± 0.12 g), and liver weight by 11.4% (3.03 ± 0.10 g vs. 3.42 ± 0.12 g) compared with the HFD group. Metabolic improvements included reductions in serum glucose (20.7%), triacylglycerol (TG) (23.5%), cholesterol (8.9%), low-density lipoprotein (LDL) (13.2%), and alanine transaminase (ALT) (63.4%). LR also decreased leptin and lipopolysaccharide (LPS) levels by 24.1% and 16.2%, suggesting reduced inflammation. Gut microbiota analysis revealed increased Firmicutes and beneficial genera (Lactobacillus, Allobaculum). LP and LD showed lesser effects, with weight gains of 8.04 ± 0.98 g and 7.21 ± 1.15 g, respectively. The superior efficacy of LR highlights its potential for obesity management, meriting further clinical exploration.
Indexed as
Identifiers
40877714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.